bluebird bio, Inc. (0HOH.L)
USD 9.28
(33.91%)
USD 9.28
(33.91%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -244.26 Million USD | 14.92% |
| 2022 | -287.09 Million USD | 51.42% |
| 2021 | -590.91 Million USD | 6.13% |
| 2020 | -629.51 Million USD | 22.48% |
| 2019 | -812.07 Million USD | -41.97% |
| 2018 | -572.02 Million USD | -72.21% |
| 2017 | -332.16 Million USD | -24.02% |
| 2016 | -267.83 Million USD | -58.44% |
| 2015 | -169.03 Million USD | -178.82% |
| 2014 | -60.62 Million USD | -143.02% |
| 2013 | -24.94 Million USD | -5.19% |
| 2012 | -23.71 Million USD | -56.62% |
| 2011 | -15.14 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -78.69 Million USD | 4.82% |
| 2024 Q2 | -88.39 Million USD | -12.33% |
| 2023 Q3 | -84.72 Million USD | 0.67% |
| 2023 Q2 | -85.29 Million USD | -1110.99% |
| 2023 Q1 | 8.43 Million USD | -66.83% |
| 2023 Q4 | -82.67 Million USD | 2.43% |
| 2023 FY | -244.26 Million USD | 14.92% |
| 2022 Q3 | -86.48 Million USD | 19.48% |
| 2022 FY | -287.09 Million USD | 51.42% |
| 2022 Q2 | -107.4 Million USD | 10.76% |
| 2022 Q1 | -120.34 Million USD | 11.29% |
| 2022 Q4 | 25.43 Million USD | 129.41% |
| 2021 Q3 | -216.95 Million USD | 9.92% |
| 2021 Q4 | -135.66 Million USD | 37.47% |
| 2021 FY | -590.91 Million USD | 6.13% |
| 2021 Q2 | -240.83 Million USD | -4.17% |
| 2021 Q1 | -231.2 Million USD | -13.35% |
| 2020 Q3 | -189.69 Million USD | -631.14% |
| 2020 Q1 | -203.42 Million USD | 11.76% |
| 2020 Q2 | -25.94 Million USD | 87.25% |
| 2020 FY | -629.51 Million USD | 22.48% |
| 2020 Q4 | -203.98 Million USD | -7.53% |
| 2019 FY | -812.07 Million USD | -41.97% |
| 2019 Q1 | -171.17 Million USD | -9.06% |
| 2019 Q2 | -202.7 Million USD | -18.42% |
| 2019 Q4 | -230.53 Million USD | -9.56% |
| 2019 Q3 | -210.41 Million USD | -3.81% |
| 2018 FY | -572.02 Million USD | -72.21% |
| 2018 Q4 | -156.96 Million USD | -4.77% |
| 2018 Q3 | -149.81 Million USD | -0.81% |
| 2018 Q2 | -148.61 Million USD | -27.42% |
| 2018 Q1 | -116.62 Million USD | 0.12% |
| 2017 Q3 | -77.65 Million USD | -14.5% |
| 2017 FY | -332.16 Million USD | -24.02% |
| 2017 Q2 | -67.82 Million USD | 2.99% |
| 2017 Q1 | -69.91 Million USD | 3.35% |
| 2017 Q4 | -116.77 Million USD | -50.37% |
| 2016 Q2 | -59.97 Million USD | -4.52% |
| 2016 Q1 | -57.38 Million USD | -17.2% |
| 2016 Q3 | -78.14 Million USD | -30.29% |
| 2016 Q4 | -72.33 Million USD | 7.43% |
| 2016 FY | -267.83 Million USD | -58.44% |
| 2015 Q1 | -24.92 Million USD | -27.07% |
| 2015 FY | -169.03 Million USD | -178.82% |
| 2015 Q2 | -52.02 Million USD | -108.71% |
| 2015 Q3 | -43.12 Million USD | 17.1% |
| 2015 Q4 | -48.96 Million USD | -13.53% |
| 2014 FY | -60.62 Million USD | -143.02% |
| 2014 Q3 | -17.01 Million USD | -27.57% |
| 2014 Q4 | -19.61 Million USD | -15.32% |
| 2014 Q1 | -10.66 Million USD | -31.46% |
| 2014 Q2 | -13.33 Million USD | -24.99% |
| 2013 Q2 | -4.19 Million USD | 35.29% |
| 2013 Q4 | -8.11 Million USD | -31.8% |
| 2013 FY | -24.94 Million USD | -5.19% |
| 2013 Q1 | -6.48 Million USD | 27.64% |
| 2013 Q3 | -6.15 Million USD | -46.8% |
| 2012 Q3 | -5.02 Million USD | -9.22% |
| 2012 Q2 | -4.6 Million USD | 10.44% |
| 2012 Q1 | -5.13 Million USD | 0.0% |
| 2012 Q4 | -8.95 Million USD | -78.26% |
| 2012 FY | -23.71 Million USD | -56.62% |
| 2011 FY | -15.14 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Editas Medicine, Inc. | -169.18 Million USD | -44.379% |
| Dynavax Technologies Corporation | -37.02 Million USD | -559.668% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | -4535.832% |
| Perrigo Company plc | 151.9 Million USD | 260.804% |
| Illumina, Inc. | -1.06 Billion USD | 77.15% |
| Thermo Fisher Scientific Inc. | 6.85 Billion USD | 103.561% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 46.964% |
| Walgreens Boots Alliance, Inc. | -14.07 Billion USD | 98.265% |
| IQVIA Holdings Inc. | 1.97 Billion USD | 112.355% |
| Heron Therapeutics, Inc. | -110.61 Million USD | -120.822% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 106.035% |
| Unity Biotechnology, Inc. | -44.66 Million USD | -446.851% |
| Waters Corporation | 817.67 Million USD | 129.873% |
| Biogen Inc. | 1.29 Billion USD | 118.836% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 10.855% |
| Evolus, Inc. | -49.23 Million USD | -396.135% |
| Adicet Bio, Inc. | -152.03 Million USD | -60.659% |
| Cara Therapeutics, Inc. | -121.49 Million USD | -101.047% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | -57.018% |
| FibroGen, Inc. | -281.81 Million USD | 13.325% |
| Agilent Technologies, Inc. | 1.35 Billion USD | 118.093% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | -441.874% |
| Homology Medicines, Inc. | -48.25 Million USD | -406.19% |
| Geron Corporation | -193.94 Million USD | -25.945% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 13.436% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | -232.356% |
| Myriad Genetics, Inc. | -123.7 Million USD | -97.463% |
| Viking Therapeutics, Inc. | -100.82 Million USD | -142.259% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 52.597% |
| Zoetis Inc. | 3.06 Billion USD | 107.959% |
| Abeona Therapeutics Inc. | -48.2 Million USD | -406.768% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 122.465% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | 225.623% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 105.671% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | -523.865% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 30.947% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 11.501% |
| Verastem, Inc. | -92.08 Million USD | -165.26% |
| Nektar Therapeutics | -137.42 Million USD | -77.742% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | -5.365% |
| Aclaris Therapeutics, Inc. | -97.35 Million USD | -150.893% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 8.798% |
| OPKO Health, Inc. | -157.02 Million USD | -55.56% |
| Exelixis, Inc. | 170.88 Million USD | 242.939% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 197.354% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | 327.682% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -338.091% |
| uniQure N.V. | -282.87 Million USD | 13.649% |
| Imunon, Inc. | -21.03 Million USD | -1061.469% |
| Blueprint Medicines Corporation | -486.27 Million USD | 49.769% |
| Insmed Incorporated | -709.62 Million USD | 65.579% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | 172.358% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 37.607% |
| TG Therapeutics, Inc. | 20.63 Million USD | 1283.841% |
| Incyte Corporation | 620.52 Million USD | 139.364% |
| Emergent BioSolutions Inc. | -726.4 Million USD | 66.374% |